Tbg Diagnostics Share Price and Company Fundamentals
Last traded: 03/17/2020
TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.
|Primary activities||A global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnostics kits, instruments and services.|
|Industry / Sector||Diagnostics & Research / Healthcare|
|Mailing address||138 Juliette Street Unit 6 Greenslopes QLD 4120 Australia|
|Phone / Fax||61 7 3088 7926 / 61 7 3394 4394|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Tbg Diagnostics does not pay dividends.
As of May 2021, following are the company executives and directors listed on Tbg Diagnostics.
|Mr. Indrajit Solomon Arulampalam||Exec. Chairman||80k|
|Ms. Generosa Hipona||CFO & GM of Fin.||170.06k|
|Mr. Justyn Peter Stedwell B.Com., B.Com||Company Sec.||49.4k|
|Mr. Willy M. Hsu||Chief Operating Officer|
|Dr. Michael Chen||Chief Scientific Officer|
|Dr. Edward Hammond||Head of Biology|
|Dr. Paul Handley||Head of Chemistry|
|Dr. Tomislav Karoli||Head of Process Chemistry|
|Mr. Ifan Chiu||Pres of TBG (Xiamen) Inc|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Tbg Diagnostics is 58.75M and its enterprise value is 59.28M. The enterprise value to revenue ratio of TDL is 12.87.
Companies similar to Tbg Diagnostics (TDL)
Tbg Diagnostics (ASX:TDL) Frequently Asked Questions
1. What is Tbg Diagnostics's Stock Symbol?
Tbg Diagnostics trades on ASX under the ticker symbol "TDL".
2. What is Tbg Diagnostics's stock price today?
One share of TDL stock can currently be purchased for approximately $0.27.
3. How can I contact Tbg Diagnostics?
Tbg Diagnostics's mailing address is 138 Juliette Street Unit 6 Greenslopes QLD 4120 Australia. The company can be reached via phone at 61 7 3088 7926.
4. What is Tbg Diagnostics's official website?
The official website of Tbg Diagnostics is http://www.tbgbio.com.
5. Which share registry manages Tbg Diagnostics's stock?
Tbg Diagnostics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.